Drug Oncology

Xospata

Payments companies reported to CMS as associated with Xospata. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.0Massociated payments (2023-2025)

4,073clinicians with associated payments

5companies reporting

By year

2023 $256K

2024 $403K

2025 $361K

Payments reported as associated with Xospata, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $492K

Medical Oncology $290K

Hematology (Internal Medicine) $89K

Internal Medicine $36K

Family $24K

Nurse Practitioner $20K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Xospata

These are the largest totals companies reported as associated with Xospata. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Mark Levis	Baltimore, MD	Medical Oncology	$100,270.21
George Yaghmour	Los Angeles, CA	Hematology & Oncology	$83,805.76
Jamie Koprivnikar	Hackensack, NJ	Medical Oncology	$77,144.55
Usama Gergis	Allentown, PA	Hematology & Oncology	$71,266.91
Mojtaba Akhtari	Omaha, NE	Hematology & Oncology	$41,967.69
Juan Varela	Orlando, FL	Hematology (Internal Medicine)	$31,506.39
Thomas Leblanc	Durham, NC	Medical Oncology	$26,466.32
Guido Marcucci	Duarte, CA	Hematology (Internal Medicine)	$25,000.00
Shin Mineishi	Hershey, PA	Medical Oncology	$23,298.58
Bradley Christensen	Dallas, TX	Hematology & Oncology	$21,226.93

Prescribed Xospata?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.